Thursday 02 May 2024
Internal Reference Number: FOI_6830
Date Request Received: 19/10/2022 00:00:00
Date Request Replied To: 25/10/2022 00:00:00
This response was sent via: By Email
Request Summary: Breast cancer
Request Category: Companies
| Question Number 1: How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: • Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) • Abemaciclib + Fulvestrant • Alpelisib + Fulvestrant • Anthracycline (e.g. doxorubicin or epirubicin) as a single agent • Atezolizumab +Nab-paclitaxel/Paclitaxel • Capecitabine as a single agent • Eribulin as a single agent or in combination • Everolimus + Exemestane • Fulvestrant as a single agent • Lapatinib • Neratinib • Parp Inhibitors (Olaparib/Talazoparib) • Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) • Palbociclib + Fulvestrant • Pembrolizumab • Platinum (e.g. carboplatin or cisplatin) as a single agent • Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) • Ribociclib + Fulvestrant • Sacituzumab Govitecan • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent • Taxane and/or Anthracycline in combination • Trastuzumab as a single agent or in combination • Trastuzumab emtansine • Transtuzumab deruxtecan • Any other active systemic anti-cancer therapy | |
| Answer To Question 1: Q. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: • Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) <5 • Abemaciclib + Fulvestrant <5 • Alpelisib + Fulvestrant 0 • Anthracycline (e.g. doxorubicin or epirubicin) as a single agent 0 • Atezolizumab +Nab-paclitaxel/Paclitaxel <5 • Capecitabine as a single agent 13 • Eribulin as a single agent or in combination <5 • Everolimus + Exemestane 0 • Fulvestrant as a single agent <5 • Lapatinib 0 • Neratinib <5 • Parp Inhibitors (Olaparib/Talazoparib) <5 • Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) 38 • Palbociclib + Fulvestrant 6 • Pembrolizumab 0 • Platinum (e.g. carboplatin or cisplatin) as a single agent <5 • Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) 0 • Ribociclib + Fulvestrant 0 • Sacituzumab Govitecan <5 • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent 5 • Taxane and/or Anthracycline in combination 6 • Trastuzumab as a single agent or in combination 47 • Trastuzumab emtansine 5 • Transtuzumab deruxtecan <5 • Any other active systemic anti-cancer therapy 6 | |
| Question Number 2: Does your trust participate in any clinical trials for breast cancer? If so, can you please provide the name of each trial and the number of patients taking part. | |
| Answer To Question 2: SFT is currently participating in 8 Research studies related to breast cancer. 3 are open to recruitment. 5 are in follow up. 5 are interventional trials. 3 are observational studies. Please see attached Word document for study names and numbers of SFT patients involved. | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
